Cargando…

Characteristics of colorectal carcinoma patients with PMS2 defects detected by immunohistochemistry

Lynch syndrome is the most prevalent form of familial colorectal cancer (CRC) and is caused by pathogenic germline mismatch repair (MMR) gene mutations. MLH1, MSH2 and MSH6 mutations have been well studied, but the rate and characteristics of PMS2 mutations are rare, especially in China. This study...

Descripción completa

Detalles Bibliográficos
Autores principales:	Zeng, Zhijun, Yan, Qijia, Chen, Guodong, Zhang, Xiaoli, Huang, Jia, Fu, Kai, Peng, Xiuda, Xiao, Shuai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2020
Materias:	Gastrointestinal Cancer
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8011511/ https://www.ncbi.nlm.nih.gov/pubmed/32826709 http://dx.doi.org/10.1097/CEJ.0000000000000620

Ejemplares similares

Immunohistochemistry‐Based Consensus Molecular Subtypes as a Prognostic and Predictive Biomarker for Adjuvant Chemotherapy in Patients with Stage II Colorectal Cancer
por: Li, Yaqi, et al.
Publicado: (2020)

Age–period–cohort effects in utilization of diagnostic procedures leading to incidental colorectal cancer detection
por: Salvatori, Andrea, et al.
Publicado: (2021)

Second Primary Malignancies in Patients with Colorectal Cancer: A Population‐Based Analysis
por: Jia, Huixun, et al.
Publicado: (2020)

Real-World Study of Characteristics and Treatment Outcomes Among Patients with KRAS p.G12C-Mutated or Other KRAS Mutated Metastatic Colorectal Cancer
por: Fakih, Marwan, et al.
Publicado: (2022)

Stereotactic Ablative Radiation Therapy for Unresectable Colorectal Oligometastases
por: Sutera, Philip, et al.
Publicado: (2018)

Relationship of HER2 Alteration and Microsatellite Instability Status in Colorectal Adenocarcinoma
por: Qiu, Miao‐Zhen, et al.
Publicado: (2021)

Adoptive T-Cell Therapy in Advanced Colorectal Cancer: A Systematic Review
por: Juat, Damie J, et al.
Publicado: (2022)

Impact of Sociodemographic Disparities and Insurance Status on Survival of Patients with Early‐Onset Colorectal Cancer
por: Salem, Mohamed E., et al.
Publicado: (2021)

Real‐World Adherence in Patients with Metastatic Colorectal Cancer Treated with Trifluridine plus Tipiracil or Regorafenib
por: Patel, Anuj K., et al.
Publicado: (2019)

The Role of Systemic Therapy in Resectable Colorectal Liver Metastases: Systematic Review and Network Meta-Analysis
por: Sonbol, Mohamad Bassam, et al.
Publicado: (2022)

The Frequency of Specific KRAS Mutations, and Their Impact on Treatment Choice and Survival, in Patients With Metastatic Colorectal Cancer
por: Fernández Montes, Ana, et al.
Publicado: (2023)

Regorafenib and Nivolumab or Pembrolizumab Combination and Circulating Tumor DNA Response Assessment in Refractory Microsatellite Stable Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2020)

Prospective Biomarker Study in Advanced RAS Wild‐Type Colorectal Cancer: POSIBA Trial (GEMCAD 10‐02)
por: García‐Albéniz, Xabier, et al.
Publicado: (2019)

Safety and Feasibility of Additional Tumor Debulking to First‐Line Palliative Combination Chemotherapy for Patients with Multiorgan Metastatic Colorectal Cancer
por: Gootjes, Elske C., et al.
Publicado: (2020)

Bevacizumab in Combination with TAS‐102 Improves Clinical Outcomes in Patients with Refractory Metastatic Colorectal Cancer: A Retrospective Study
por: Fujii, Hironori, et al.
Publicado: (2019)

Cetuximab and Irinotecan With or Without Bevacizumab in Refractory Metastatic Colorectal Cancer: BOND-3, an ACCRU Network Randomized Clinical Trial
por: Lipsyc-Sharf, Marla, et al.
Publicado: (2022)

Muscle Loss Is Associated with Overall Survival in Patients with Metastatic Colorectal Cancer Independent of Tumor Mutational Status and Weight Loss
por: Best, Till Dominik, et al.
Publicado: (2021)

BRAF Mutations Are Associated with Poor Survival Outcomes in Advanced-stage Mismatch Repair-deficient/Microsatellite High Colorectal Cancer
por: Tan, Elaine, et al.
Publicado: (2022)

Reinduction of an Anti-EGFR-based First-line Regimen in Patients with RAS Wild-type Metastatic Colorectal Cancer Enrolled in the Valentino Study
por: Fucà, Giovanni, et al.
Publicado: (2022)

Efficacy and Safety of Cetuximab Dosing (biweekly vs weekly) in Patients with KRAS Wild-type Metastatic Colorectal Cancer: A Meta-analysis
por: Parikh, Aparna R, et al.
Publicado: (2022)

Mucinous Histology Is Associated with Resistance to Anti-EGFR Therapy in Patients with Left-Sided RAS/BRAF Wild-Type Metastatic Colorectal Cancer
por: Wang, Chongkai, et al.
Publicado: (2022)

Extended RAS Analysis of the Phase III EPIC Trial: Irinotecan + Cetuximab Versus Irinotecan as Second‐Line Treatment for Patients with Metastatic Colorectal Cancer
por: Sobrero, Alberto, et al.
Publicado: (2020)

Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes
por: Bekaii-Saab, Tanios S, et al.
Publicado: (2023)

Prevalence of KRAS G12C Mutation and Co-mutations and Associated Clinical Outcomes in Patients With Colorectal Cancer: A Systematic Literature Review
por: Strickler, John H, et al.
Publicado: (2023)

A Belgian Population-Based Study Reveals Subgroups of Right-sided Colorectal Cancer with a Better Prognosis Compared to Left-sided Cancer
por: Janssens, Katleen, et al.
Publicado: (2023)

Antibiotic Exposure Does Not Impact Immune Checkpoint Blockade Response in MSI-H/dMMR Metastatic Colorectal Cancer: A Single-Center Experience
por: Serpas Higbie, Victoria, et al.
Publicado: (2022)

Placenta-specific protein 1 enhances liver metastatic potential and is associated with the PI3K/AKT/NF-κB signaling pathway in colorectal cancer
por: Ma, Jiachi, et al.
Publicado: (2020)

Alarming Drop in Early Stage Colorectal Cancer Diagnoses After COVID-19 Outbreak: A Real-World Analysis from the Italian COVID-DELAY Study
por: Mentrasti, Giulia, et al.
Publicado: (2022)

BRAF (V600E)/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint Inhibitors
por: Colle, Raphael, et al.
Publicado: (2023)

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF (V600E)-Mutant KRAS Wild-Type Metastatic Colorectal Cancer
por: Tabernero, Josep, et al.
Publicado: (2023)

Withholding the Introduction of Anti‐Epidermal Growth Factor Receptor: Impact on Outcomes in RAS Wild‐Type Metastatic Colorectal Tumors: A Multicenter AGEO Study (the WAIT or ACT Study)
por: Palmieri, Lola‐Jade, et al.
Publicado: (2019)

The McCAVE Trial: Vanucizumab plus mFOLFOX‐6 Versus Bevacizumab plus mFOLFOX‐6 in Patients with Previously Untreated Metastatic Colorectal Carcinoma (mCRC)
por: Bendell, Johanna C., et al.
Publicado: (2019)

Propensity Score Analysis of Regorafenib Versus Trifluridine/Tipiracil in Patients with Metastatic Colorectal Cancer Refractory to Standard Chemotherapy (REGOTAS): A Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study
por: Moriwaki, Toshikazu, et al.
Publicado: (2017)

Appearances of screen-detected versus symptomatic colorectal cancers at CT colonography
por: Plumb, Andrew A., et al.
Publicado: (2016)

Magnetic resonance (MR) colonography in the detection of colorectal lesions: a systematic review of prospective studies
por: Zijta, Frank M., et al.
Publicado: (2009)

Lymphopenia in Esophageal Squamous Cell Carcinoma: Relationship to Malnutrition, Various Disease Parameters, and Response to Concurrent Chemoradiotherapy
por: Zhou, Xi‐Lei, et al.
Publicado: (2019)

Activity of Anlotinib in the Second-Line Therapy of Metastatic Gastrointestinal Stromal Tumors: A Prospective, Multicenter, In Vitro Study
por: Zhou, Yongjian, et al.
Publicado: (2023)

Perioperative Chemotherapy Could Not Improve the Prognosis of Gastric Cancer Patients With Mismatch Repair Deficiency: A Multicenter, Real-World Study
por: Zhao, Lulu, et al.
Publicado: (2023)

Toripalimab Plus Paclitaxel and Carboplatin as Neoadjuvant Therapy in Locally Advanced Resectable Esophageal Squamous Cell Carcinoma
por: He, Wenwu, et al.
Publicado: (2022)

Germline PMS2 mutation screened by mismatch repair protein immunohistochemistry of colorectal cancer in Japan
por: Sugano, Kokichi, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_5af6803f8a8isi3maenn52oafa